

Anaesthesia recommendations for **Insulinoma**

Disease name: Insulinoma

ICD 10: D13.7 (benign), C25.4 (malignant), D37.8 (uncertain behaviour)

Synonyms: -

Disease summary: Insulinoma is a rare neuroendocrine tumour of the pancreas, which is usually small, solitary and benign. It may be part of multiple endocrine neoplasia tupe 1 syndrome. It is characterised by hypoglycaemic episodes as a result of inappropriate secretion of insulin from the pancreatic adenoma cells. Whipple's triad is pathognomic of insulinoma, which includes: 1) symptoms of neuroglycopaenia, 2) documented hypoglycaemia (plasma glucose level less than 50 mg/dL) and 3) relief of symptoms (often within 5-10 min) following glucose administration. Documented hyperinsulinism in presence of hypoglycaemia warrants further investigations to confirm the diagnosis. Gold standard for the diagnosis is 72-h fasting test, demonstration of Whipple's triad. The localisation of the tumour is a challenge for the clinicians. Surgical resection is the curative treatment with a high success rate. Intraoperative ultrasound and surgical palpation confirm the site of the tumour. There may be severe hypoglycaemia during surgical handling of the tumour, symptoms of which may be masked when the patient is under anaesthesia. So the main anaesthetic concern is to maintain optimum plasma glucose level. Glucose infusion and frequent plasma glucose monitoring to maintain glucose level more than 60 mg/DL is found to be helpful.

Medicine is in progress



Perhaps new knowledge

Every patient is unique

Perhaps the diagnosis is wrong



Find more information on the disease, its centres of reference and patient organisations on Orphanet: www.orpha.net

Typical surgery

Surgical excision of insulinoma, Laparoscopic resection of insulinoma, enucleation of insulinoma, distal pancreatectomy.

Type of anaesthesia

Regarding anaesthetic agents, no specific recommendations are available. Combination of general anaesthesia with propofol, epidural block and opioid as part of multimodal anaesthesia is a useful choice of anaesthesia for the removal of insulinoma. The anaesthetic technique should include drugs that decrease the cerebral metabolic rate for oxygen (CMRO₂). Both thiopentone sodium and propofol reduce CMRO₂. Propofol has an advantage over thiopentone sodium, as the latter one can cause severe hypotension in patients receiving diazoxide therapy because both are protein-bound drugs. Moreover, propofol has no effect on the release of insulin and glucose regulation. Although enflurane and halothane are not much in use now, they inhibit pancreatic insulin release, resulting into hyperglycaemia.

Necessary additional pre-operative testing (beside standard care)

In addition to standard care, it is important to confirm the diagnosis of insulinoma.

The 72-h fasting test is a demonstration of Whipple's triad of symptoms, which is considered as the gold standard for the diagnosis. Insulinoma is diagnosed when the following criteria are fulfilled:

1. Blood glucose less than 50 mg/dL with hypoglycaemic symptoms
2. Relief of symptoms after meal
3. Elevated C-peptide (>200 pmol/L)
4. Absence of plasma sulfonylurea
5. Increased serum insulin level (>5–10 µU/mL)
6. Increased proinsulin level (≥25% or ≥22 pmol)

Other tests include: Intravenous secretin test of insulinoma, C-peptide inhibition test etc., and can be used to diagnose insulinoma.

Then localisation of the tumour may be a challenge, as it is a very small and intrapancreatic tumour. The success rate of non-invasive modalities is poor, as shown in different studies. In case of transabdominal ultrasound, it is 9–66%, in computed tomography (CT) 50–80%, in magnetic resonance imaging (MRI) 40–70% and in somatostatin receptor scintigraphy 17%.

The overall success rate of all these modalities together is around 80%. CT and MRI are helpful to detect metastatic disease. The use of endoscopic ultrasound (EUS) has increased recently. The sensitivity of EUS is reported as 40–93%. Invasive modalities like Pancreatic arteriography, which was considered as the “gold standard”, is now not in much in use.

Transhepatic portal venous sampling (THPVS) was also considered as one of the most accurate tools for localisation. Intraarterial calcium stimulation test or arterial stimulation and venous sampling (ASVS) has almost replaced THPVS now. Intraoperative ultrasound (IOUS) is a very useful tool of localising the insulinoma, especially when it is small and not easily palpable. IOUS can localise insulinoma in almost 86-90% of the cases.

Particular preparation for airway management

Usually, insulinoma does not affect the airway and therefore no particular preparation is required.

Particular preparation for transfusion or administration of blood products

As the surgery is either laparotomy and resection of tumour or laparoscopic enucleation of the tumour, the preparation for the transfusion of blood products is similar to any other major laparotomy or laparoscopic procedure.

Particular preparation for anticoagulation

There is no evidence to support the need of anticoagulation. But the patients with malignant insulinoma as a part of MEN1 syndrome, may have a higher risk of postoperative thrombosis.

Particular precautions for positioning, transportation and mobilisation

Not reported.

Interactions of chronic disease and anaesthesia medications

These patients are often on diazoxide, which reduces insulin secretion. Thiopentone Sodium can cause severe hypotension as both of these drugs are protein-bound drugs. Enflurane and halothane inhibit pancreatic insulin release, which results in hyperglycaemia. This inhibitory effect is higher with enflurane than with sevoflurane and desflurane.

Anaesthetic procedure

The patient should get admitted 1 day prior to the scheduled surgery. Intravenous infusion of 10% dextrose should be started for the fasting period. Frequent glucose monitoring is important to prevent plasma glucose level to fall below 40–50 mg/dL at any time. Diazoxide and somatostatin analogues are continued in the morning of surgery to reduce insulin secretion intraoperatively while handling of the tumour.

General anaesthesia with epidural block is a preferred technique of anaesthesia. Thiopentone sodium is to be avoided for induction. Among inhalational agents, enflurane and halothane should be avoided.

Particular or additional monitoring

The main concern of anaesthetic management is to prevent hypoglycaemia until tumour resection and the control of rebound hyperglycaemia soon after resection. Various approaches have been described, including use of “artificial pancreas”, which continuously monitors plasma glucose and delivers glucose or insulin to maintain a predetermined glucose level, but, it is not much in use due to its costs and complexity. Another suggested approach is continuous infusion of 10% glucose and every 15 minutes monitoring of blood glucose levels to maintain plasma glucose in the range of 100–150 mg/dL. This method helps to detect sudden hypo- or hyperglycaemia. Other groups recommended this frequency of sampling every 30 minutes. Some surgical groups prefer to maintain moderate hypoglycaemia so that post-resection increase in plasma glucose concentration can be used as an indication of successful tumour removal. But, this technique can lead to severe hypoglycaemia intraoperatively, and hyperglycaemic rebound is not adequately reliable as there are reports of both false-positive and -negative responses. Therefore, this large swing in plasma glucose during handling of the tumour should be carefully monitored and maintained.

Possible complications

Hypoglycaemia until tumour resection and rebound hyperglycaemia after resection.

Post-operative care

Usually the blood glucose rapidly comes back to the normal level after resection of insulinoma, but it may take several hours to several days. During the postoperative period, support by glucose infusion along with strict monitoring helps to maintain optimum level of blood glucose. In this process, the blood glucose level may rise up to 180–230 mg/dL, which may require small doses of insulin. It is recommended to measure the blood glucose level frequently during hospitalisation and once daily after discharge.

Disease-related acute problems and effect on anaesthesia and recovery

A disease related acute problem is severe hypoglycaemia and associated problems. There may be neurological damage due to a previous hypoglycaemic episode, which should be documented.

Adequate NPO may not be achieved as patients may become symptomatic even after a few hours of fasting and due to poor patient compliance. Hence the risk of aspiration must be considered while inducing these patients and adequate care must be taken.

Rebound hyperglycaemia and associated problem may be a concern during recovery.

Ambulatory anaesthesia

The management should be the same.

Obstetrical anaesthesia

Considering the maintenance of the mother-foetus binomial and a safe clinical treatment, the use of diet supervised by specialist and use of drugs such as diazoxide, beta blockers, calcium channel blockers, and octreotide are considered.

Regarding anaesthetic management in these patients, the main goal is same as in non-pregnant patients i.e. prevention of hypoglycaemia and controlling the hyperglycaemic rebound after resection. Therefore, perioperative and postoperative monitoring and control to prevent major changes in blood glucose levels is recommended.

References

1. Harris S. Hyperinsulinism and dysinsulinism. *JAMA* 1924;83:729–33
2. Whipple AO, Frantz VK. Adenoma of islet cells with hyperinsulinism. *Ann Surg* 1935; 101:1299–1365
3. Markowitz AM, Slanetz CA Jr, Frantz VK. Functioning Islet Cell Tumors of the Pancreas: 25-Year Follow up. *Ann Surg* 1961;154:877–884
4. Jyotsna VP, Rangel N, Pal S, Seith A, Sahni P, Ammini AC. Insulinoma: Diagnosis and surgical treatment. Retrospective analysis of 31 cases. *Indian J Gastroenterol* 2006;25:244–247
5. Vaidakis D, Karoubalis J, Pappa T, Piaditis G, Zografos GN. Pancreatic insulinomas: Current issues and trends. *Hepatobiliary Pancreat Dis Int* 2010;9:234–241
6. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. *Br J Surg* 2006;93:264–275
7. Abboud B, Boujaoude J. Occult sporadic insulinoma: Localization and surgical strategy. *World J Gastroenterol* 2008;14:657–665
8. Mathur A, Gorden P, Libutti SK. Insulinoma. *Surg Clin North Am* 2009;89:1105–1121
9. Jensen RT. Pancreatic neuroendocrine tumours: Overview of recent advances and diagnosis. *J Gastrointestinal Surg* 2006;10:324–326
10. Nikfarjam M, Warshaw AL, Axelrod L, Deshpande V, Thayer SP, Ferrone CR, et al. Improved contemporary surgical management of insulinoma: A 25-year experience at the Massachusetts General Hospital. *Ann Surg* 2008;247:165–172
11. Falconi M, Bettini R, Boninsegna L, Crippa S, Butturini G, Pederzoli P. Surgical strategy in the treatment of pancreatic neuroendocrine tumours. *J Pancreas* 2006;7:150–156
12. Cupisti K, Höppner W, Dotzenrath C, Simon D, Berndt I, Röher HD, et al. Lack of MEN1 gene mutations in 27 sporadic insulinomas. *Eur J Clin Invest* 2000;30:325–329
13. Lairmore TC, Moley JF. Endocrine pancreatic tumors. *Scand J Surg* 2004;93:311–315
14. Coelho C, Druce MR, Grossman AB. Diagnosis of insulinoma in a patient with hypoglycemia without obvious hyperinsulinemia. *Nat Rev Endocrinol* 2009;5:628–631
15. Cryer PE, Axelrod L, Grossman AB, Heller SR, Montori VM, seaquist ER, et al. Evaluation and Management of Adult Hypoglycemic Disorders: An Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 2009;94:709–728
16. Service FJ, Natt N. The prolonged fast. *J Clin Endocrinol Metab* 2000;85:3973–3974
17. Hirshberg B, Livi A, Bartlett DL, Libutti SK, Alexander HR, Doppman JL, et al. Forty-Eight-Hour Fast: The Diagnostic Test for Insulinoma. *J Clin Endocrinol Metab* 2000;85:3222–3226
18. Imamura M, Hattori Y, Nishida O, Honda T, Shimada Y, Miyahara T, et al. Unresponsiveness of insulinoma cells to secretin: Significance of secretin test in patient with insulinoma. *Pancreas* 1990;5:467–473
19. Service FJ, O'Brien PC, Kao PC, Young WF Jr. C-peptide suppression test: Effects of gender, age, and body mass index; implications for the diagnosis of insulinoma. *J Clin Endocrinol Metab* 1992;74:204–210
20. Guettier JM, Kam A, Chang R, Skarulis MC, Cochran C, Alexander HR, et al. Localization of Insulinomas to Regions of the Pancreas by Intraarterial Calcium Stimulation: The NIH Experience. *J Clin Endocrinol Metab* 2009;94:1074–1080
21. Lo CY, Chan FL, Tam SC, Cheng PW, Fan ST, Lam KS. Value of intra-arterial calcium stimulated venous sampling for regionalization of pancreatic insulinomas. *Surgery* 2000; 128:903–909
22. Imamura M, Minematsu S, Suzuki T, Takahashi K, Shimada Y, Tobe T, et al. Usefulness of selective arterial secretin injection test for localization of gastrinoma in the Zollinger-Ellison syndrome. *Ann Surg* 1987;205:230–239
23. Nakagawa M, Sasakuma F, Kishi Y, Ishikawa O. A successful monitoring for intraoperative calcium stimulation test in complete resection of pancreatic insulinoma. *Anesth Analg* 2001;93:239–240
24. Moreno MP, Guierrez AC, Munoz-Villanueva MC, Ortega RP, Corpas JM, Zurera TL, et al. Usefulness of arterial calcium stimulation with hepatic venous sampling in the localization diagnosis of endogenous hyperinsulinism. *Endocrinol Nutr* 2010;57:95–99
25. Norton JA. Intraoperative methods to stage and localize pancreatic and duodenal tumours. *Ann Oncol* 1999;10:182–184
26. Shin LK, Brant-Zawadzki G, Kamaya A, Jeffrey RB. Intraoperative ultrasound of the pancreas. *Ultrasound Q* 2009;25:39–48

27. Rostambeigi N, Thompson GB. What should be done in an operating room when an insulinoma cannot be found? *Clin Endocrinol* 2009;70:512–515
28. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited Pancreatic Endocrine Tumor Syndromes: Advances in molecular pathogenesis, diagnosis, management and controversies. *Cancer Supp*2008;113:1807–1843
29. Grant CS. Insulinoma. *Best Pract Res Clin Gastroenterol* 2005;19:783–798
30. Healy ML, Dawson SJ, Murray RM, Zalberg J, Jefford M. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. *Internal Med J* 2007;37:406–409
31. Gordon P, Comi RJ, Maton PN, Go VL. NIH Conference. Somatostatin and Somatostatin Analogue (SMS 201-995) in treatment of Hormone-Secreting Tumors of the Pituitary and Gastrointestinal Tract and Non-Neoplastic Diseases of the Gut. *Ann Intern Med* 1989;110:35–50
32. Arnold R, Wied M, Behr TH. Somatostatin analogues in the treatment of endocrine tumours of the gastrointestinal tract. *Expert Opin Pharmacother* 2002;3:643–656
33. Novotny J, Janku F, Mares P, Petruzelka L. Symptomatic control of hypoglycaemia with prednisone in refractory metastatic pancreatic insulinoma. *Support Care Cancer* 2005;13:760–762
34. Chari P, Pandit SK, Kataria RN, Singh H, Baheti DK, Wig J. Anaesthetic management of insulinoma. *Anaesthesia* 1977;32:261–264
35. Akhtaruzzaman AK, Dhar S, Asaduzzaman AK, Samad MA, Laskar MH, Kamal M, et al. Anaesthetic management for hand assisted laparoscopic enucleation of pancreatic insulinoma. *JBSA* 2008;21:50–52
36. Hirshberg B, Libutti SK, Alexander HR, Bartlett DL, Cochran C, Livi A, et al. Blind distal pancreatectomy for occult insulinoma, an inadvisable procedure. *J Am Coll Surg* 2002;194:761–764
37. Burch PG, McLeskey CH. Anaesthesia for patients with insulinoma treatment with oral diazoxide. *Anaesthesiology* 1981;55:472–475
38. Grant F. Anesthetic considerations in the multiple endocrine neoplasia syndromes. *Curr Opin Anaesthesiol* 2005;18:345–352
39. Maciel RT, Fernandes FC, Pereira Ldos S. Anesthesia in a patient with multiple endocrine abnormalities. Case report. *Rev Bras Anestesiol* 2008;58:172–178
40. Sato Y, Onozawa H, Fujiwara C, Kamide M, Tanifuji Y, Amaki Y. Propofol anesthesia for a patient with insulinoma. *Masui* 1998;47:738–741
41. Kunisawa T, Takahata O, Yamamoto Y, Sengoku K, Iwasaki H. Anesthetic management of two patients with insulinoma using propofol in association with rapid immunoassay for insulin. *Masui* 2001;50:144–149
42. Ewart RB, Rusy BF, Bradford MW. Effects of enflurane on release of insulin by pancreatic islets in vitro. *Anesth Analg* 1981;60:878–884
43. Gingerich R, Wright PH, Paradise RR. Effects of halothane on glucose stimulated insulin secretion and glucose oxidation in isolated rat pancreatic islets. *Anaesthesiology* 1980;53:219–22
44. Muir JJ, Endres SM, Offord K, Heerden JA, Tinker JH. Glucose management in patients undergoing operation for insulinoma removal. *Anaesthesiology* 1983;59:371–375
45. Bourke AM. Anaesthesia for the surgical treatment of hyperinsulinism. *Anaesthesia* 1966;21:239–243
46. Schwartz SS, Horwitz DL, Zehfus B, Langer BG, Kaplan E. Continuous monitoring and control of plasma glucose during operation for removal of Insulinoma. *Surgery* 1979;85:702–707
47. Harrison TS, Child CG 3rd, Fry WJ, Floyd JC Jr, Fajans SS. Current surgical management of functioning islet cell tumours of the pancreas. *Ann Surg* 1973;178:485–495
48. Motoko M, Hiroshi M, Moritoki EG, Satoshi S, Ryuji K, Masaki M et al. Anesthetic management of pediatric patients with insulinoma using continuous glucose monitoring. *Masui* 2009; 58:757–759
49. Strong VE, Shifrin A, Inabnet WB. Rapid intraoperative insulin assay: A novel method to differentiate insulinoma from nesidioblastosis in the pediatric patient. *AnnSurg Innov Res* 2007;24;1:6
50. Joris JL. Anesthesia for Laparoscopic Surgery. *Miller's Anesthesia* 7th Ed; Churchill Livingstone Elsevier. Philadelphia 2010:2185–2202
51. Muralidhar V. Physiology of Pneumoperitoneum and Anaesthesia in Laparoscopic Surgery. Available from: <http://www.iages.org.in/media/files/chapter6> [Last cited on 2011 Oct 2]

52. Braga AFA, Braga FSS, Zen JH Junior, Brandao MJN, Marcondes GA, Barbosa TDA. Insulinoma and pregnancy: anesthesia and perioperative management. *Revista Brasileira de Anestesiologia* 2017;67:426–429. Accessed on 14 May 2019
53. Luo Y, Pan Q, Yao S, Yu M, Wu W, Xue H, et al. Glucagon-Like Peptide-1 Receptor PET/CT with ⁶⁸Ga-NOTA-Exendin-4 for Detecting Localized Insulinoma: A Prospective Cohort Study. *J Nucl Med.* 2016;57:715–720.

Date last modified: **March 2020**

This recommendation was prepared by:

Author(s)

Jyotsna Goswami, Department of Anaesthesia & Critical Care, Tata Medical Center,
Kolkata, India
jyotsnagoswami@gmail.com

Disclosure The author has no financial or other competing interest to disclose. This recommendation was unfunded.

This recommendation was reviewed by:

Reviewers

Markus Weigand, Anaesthesiologist, University-Clinic Heidelberg, Germany
markus.weigand@med.uni-heidelberg.de

Lars Kihm, Internist, University-Clinic Heidelberg, Germany
lars.kihm@med.uni-heidelberg.de

Simon Schimmack, Surgeon, endocrinological surgery, University-Clinic Heidelberg,
Germany
Simon.Schimmack@med.uni-heidelberg.de

Disclosure The reviewers have no financial or other competing interest to disclose.
